FDA approvals for Mirum, AbbVie Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 28 September, 2026

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

presented by When "Un­de­tectable" Is­n't Enough: How ctD­NA Clear­ance Is Re­shap­ing Drug De­vel­op­ment

news Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer FDA approves Mirum’s drug for ultra-rare soft tissue disease  AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

Endpoints 11: The Class of 2026 Endpoints 11: Vivodyne’s human tissue factory could change how drugs are tested before they reach patients Endpoints 11: Stipple Bio is taking precision to the next level Endpoints 11: SonoThera is making waves in a bold new approach to non-viral gene therapy Endpoints 11: NewLimit searches far beyond Yamanaka for a new class of anti-aging medicines Endpoints 11: Medra wants to create self-driving labs that change how scientists work Endpoints 11: Science superstar-backed Medici Therapeutics believes the future of cancer therapy must be highly personalized Endpoints 11: Kali Therapeutics almost bought drugs from China. Instead, its in-house pipeline is thriving Endpoints 11: Ying Huang’s K2 crew looks to marry China’s speed with global expertise